E.E.S. 200

Post-LOE

erythromycin ethylsuccinate

R-Pharm US

ANDAORALSUSPENSION

Approved

Oct 1973

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

E.E.S. 200 (erythromycin ethylsuccinate) by R-Pharm US is clinical pharmacology orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed under both fasting and nonfasting conditions. Approved for the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 8 more indications. First approved in 1973.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed under both fasting and nonfasting conditions. Erythromycin diffuses readily into most body fluids. Only low concentrations are normally achieved in the spinal fluid, but passage of the…

Worked on E.E.S. 200 at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

E.E.S. 200

Mechanism of Action

Indications (11)